<DOC>
	<DOC>NCT01176968</DOC>
	<brief_summary>Administration of eplerenone within 24 hours of onset of symptoms of myocardial infarction, in patients without heart failure, reduces cardiovascular mortality / morbidity.</brief_summary>
	<brief_title>Impact Of Eplerenone On Cardiovascular Outcomes In Patients Post Myocardial Infarction</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Eplerenone</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<criteria>Subjects must have experienced a myocardial infarction (STEMI) within the previous 24 hours confirmed by symptoms and ECG. Subjects with a known low ejection fraction of less than 40% or any previous history of heart failure. Subjects treated with eplerenone or other aldosterone antagonists within the past 1 month. The subject has uncontrolled hypotension (SBP&lt;90mmHg). Subjects with eGFR ≤30ml/min (based on admission serum creatinine and the MDRD formula) or serum creatinine ≥220µmol/L.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Eplerenone</keyword>
	<keyword>myocardial infarction</keyword>
	<keyword>mortality</keyword>
	<keyword>morbidity</keyword>
</DOC>